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The European Academy of Tumor Immunology (EATI, official website: http://eati.landesbioscience.com/index.html) has
been founded in 2011 with the idea of creating a novel organization that responds to the need of structuring the
European research space in this expanding, clinically ever more important area of research. Rapidly, this initiative, which
regroups (part of) the elite of tumor immunologists, has been joined by 110 scientists, who accepted to join EATI as
founding members. Obviously, EATI will not enter in competition with existing prestigious organizations, be they
supranational (such as the Cancer Research Institute, CRI; the European Society for Cancer Immunology and
Immunotherapy, ESCII; and the Society for the Immunotherapy of Cancer, SITC), or national [such as the Cancer
Immunology Working Group, CIMM, of the American Association for Cancer Reserch; the (German) Association for Cancer
Immunotherapy, CIMT; the (US) Cancer Immunotherapy Consortium, CIC; the (US) Cancer Vaccine Consortium, CVC; and
the Italian Network for Cancer Biotherapy, NIBIT]. The choice of cooperation (rather than competition) with these
organizations is clearly documented by the fact that many prominent members of CIMM, CIC, CIMT, CRI, CVC, ESCII, NIBIT
and SITC are also EATI Academicians.
As true for all other aforementioned
organizations, the principal objective of
the European Academy of Tumor
Immunology (EATI) will be to promote
tumor immunology at the scientific and
clinical levels. EATI will strive for excel-
lence, independence, leadership, diversity
and flexibility. Throughout its work, EATI
will provide independent, authoritative and
evidence-based advice to underpin policy
for stimulating the implementation of
concepts, methods and procedures inspired
by tumor immunology. In particular EATI
will devote itself to serve as bridge between
fields, continents and generations. What
does this mean in practical terms?
Bridging Fields
EATI will engage in all areas of tumor
immunology, considered as a continuum
between fundamental, translational and
clinical research, as well as the practical
implementation of diagnostic and thera-
peutic procedures in routine clinical
practice. Indeed, EATI considers that even
the most fundamental aspects of immuno-
logy and (cancer) cell biology require
further in depth investigation to launch
the next wave of conceptual insights. It
may take several decades to apply a basic
discovery in the clinics, as exemplified by
the time that elapsed from the discoveries
of monoclonal antibodies, dendritic cells
and papilloma virus to their application in
clinical oncology. Although this time
frame certainly deters the pharmaceutical
and biotechnical industries—bound to
short-term vision—from investing in basic
science, EATI believes that basic research
constitutes one of the best investments
that public administrations can effectuate
to ameliorate patient care in the future
including in the area of cancer immu-
notherapy. Obviously, EATI will not
neglect the translational and clinical aspect
of tumor immunology. Indeed, EATI will
be one of the protagonists of the yet-to-be-
created European Cancer Immunotherapy
Alliance (Euro-CIA), which will launch
several multicenter trials in the Old
Continent.
Bridging Continents
In spite of the appearance of its name,
EATI is not an exclusively European
organization. Close to half of its founding
members are from other continents
(Europeans do not dare to say “rest of the
world”), 42 from the Americas, five from
Asia and one from Australia. This matter of
fact illustrates the efforts of EATI to act
as an intercontinental, global organization
that pursues its goals without any local
patriotism. Our common enemies are the
dominant characteristics of the abysmally
anti-scientific society that surrounds us,
in all countries of this globe: superficial
hedonism, facile consumerism, immoral
profit-seeking and political shortsightness.
So, it is our moral obligation to pool our
energy, knowledge and resources to pub-
licize our vision and to convince policy
makers, public administrations, industrial
partners and health care professionals that
tumor immunology has a huge potential
for the prevention and treatment of
neoplastic diseases.
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Bridging Generations
The founding members of EATI have
made essential contributions to tumor
immunology (and three among them
actually won the Nobel prize), meaning
that they (mostly) attained the second half
of their life expectancy. Notwithstanding
this accumulated experience, EATI is
aware of the necessity to stimulate and
educate the next generation of tumor
immunologists. In collaboration with the
“LabEx Immuno-Oncology” (a network of
laboratories specialized in tumor immuno-
logy that is sponsored by the French
Government), EATI will sponsor several
educational graduate student programs in
Paris, support graduate and post-doctoral
researchers working in the Paris area,
launch a seminar series on the immuno-
therapy of cancer in Paris and hold
(at least one) annual meeting that will
give educational credits to PhD students.
Although these programs are right now
limited to Paris, EATI plans to extend
these efforts across Europe via its coopera-
tion with the European Federation of
Immunology Societies (EFIS) and the
European Academy of Cancers Sciences
(EACS). These educational activities will
be publicized in part via OncoImmunology,
which is the official EATI journal.
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